comparemela.com

Latest Breaking News On - Molecular therapeutic - Page 11 : comparemela.com

4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock

EMERYVILLE, Calif., May 04, 2023 4D Molecular Therapeutics, Inc. , a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large. | May 4, 2023

4D Molecular Therapeutics Inc (FDMT) Announces Proposed $100M Share Offering

4D Molecular Therapeutics Inc (FDMT) Announces Proposed $100M Share Offering
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

FY2024 Earnings Forecast for 4D Molecular Therapeutics, Inc (NASDAQ:FDMT) Issued By SVB Leerink

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Rating) – Analysts at SVB Leerink raised their FY2024 earnings per share estimates for shares of 4D Molecular Therapeutics in a report issued on Thursday, April 13th. SVB Leerink analyst M. Foroohar now expects that the company will post earnings of ($2.48) per share for the year, up […]

Financial Survey: Vaxart (NASDAQ:VXRT) and 4D Molecular Therapeutics (NASDAQ:FDMT)

Vaxart (NASDAQ:VXRT – Get Rating) and 4D Molecular Therapeutics (NASDAQ:FDMT – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings. Risk and Volatility Vaxart has a beta of 0.82, […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.